Feasibility and preliminary effectiveness of virtual reality as a patient education tool for people with cancer undergoing immunotherapy: a protocol for a randomised controlled pilot study in a regional setting
- Author(s)
- van der Kruk, SR; Gunn, KM; MacDougall, H; Milne, D; Smith, K; Zielinski, R;
- Details
- Publication Year 2023-06-13,Volume 13,Issue #6,Page e071080
- Journal Title
- BMJ Open
- Publication Type
- Protocol
- Abstract
- INTRODUCTION: Patient education is a critical component of healthcare delivery. However, medical information and knowledge are complex and can be difficult for patients and families to comprehend when delivered verbally. The use of virtual reality (VR) to convey medical information to patients may bridge this communication gap and lead to more effective patient education. It may be of increased value to those with low health literacy and levels of patient activation, in rural and regional settings. The objective of this randomised, single-centre pilot study is to examine the feasibility and preliminary effectiveness of VR as an education tool for people with cancer. The results will provide data to inform the feasibility of a future randomised controlled trial, including sample size calculations. METHODS AND ANALYSIS: Patients with cancer undergoing immunotherapy will be recruited. A total of 36 patients will be recruited and randomised to one of three trial arms. Participants will be randomised 1:1:1 to receive VR, a two-dimensional video or standard care (ie, verbal communication and information leaflets). Feasibility will be assessed by recruitment rate, practicality, acceptability, usability and related adverse events. The potential impact of VR on patient-reported outcomes (ie, perceived information provision quality, knowledge about immunotherapy and patient activation) will be assessed and stratified by information coping style (ie, monitors vs blunters) whenever statistical analyses are significant. The patient-reported outcomes will be measured at baseline, post-intervention and 2 weeks post-intervention. In addition, semistructured interviews will be conducted with health professionals and participants randomised to the VR trial arm, to further explore acceptability and feasibility. ETHICS AND DISSEMINATION: Ethics approval was obtained from the Greater Western Human Research Ethics Committee, New South Wales Local Health District (2022/ETH01760). Informed consent will be obtained from all participants. Findings will be disseminated via relevant conference presentations and publications in peer-reviewed journals. TRIAL REGISTRATION NUMBER: ACTRN12622001473752.
- Publisher
- BMJ
- Keywords
- Humans; Feasibility Studies; Pilot Projects; *Patient Education as Topic; *Neoplasms/therapy; Immunotherapy; Randomized Controlled Trials as Topic; Oncology; Virtual Reality
- Department(s)
- Medical Oncology
- PubMed ID
- 37311632
- Publisher's Version
- https://doi.org/10.1136/bmjopen-2022-071080
- Open Access at Publisher's Site
https://doi.org/10.1136/bmjopen-2022-071080- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-10-12 07:16:45
Last Modified: 2023-10-12 07:16:59